KR20120002129A - 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 - Google Patents
면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 Download PDFInfo
- Publication number
- KR20120002129A KR20120002129A KR1020100062860A KR20100062860A KR20120002129A KR 20120002129 A KR20120002129 A KR 20120002129A KR 1020100062860 A KR1020100062860 A KR 1020100062860A KR 20100062860 A KR20100062860 A KR 20100062860A KR 20120002129 A KR20120002129 A KR 20120002129A
- Authority
- KR
- South Korea
- Prior art keywords
- immunoglobulin
- facviia
- region
- conjugate
- facvii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100062860A KR20120002129A (ko) | 2010-06-30 | 2010-06-30 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
| ARP110102301A AR082032A1 (es) | 2010-06-30 | 2011-06-29 | Complejo de factor viia en el que se utiliza un fragmento de inmunoglobulina |
| CN2011800325807A CN103025358A (zh) | 2010-06-30 | 2011-06-30 | 使用免疫球蛋白片段的因子viia复合物 |
| PCT/KR2011/004796 WO2012002745A2 (en) | 2010-06-30 | 2011-06-30 | Factor viia complex using an immunoglobulin fragment |
| US13/807,572 US20130095090A1 (en) | 2010-06-30 | 2011-06-30 | Factor viia complex using an immunoglobulin fragment |
| EP11801151.9A EP2588142A2 (en) | 2010-06-30 | 2011-06-30 | Factor viia complex using an immunoglobulin fragment |
| TW100123053A TWI443106B (zh) | 2010-06-30 | 2011-06-30 | 使用免疫球蛋白片段之VIIa因子錯合物 |
| JP2013518254A JP2013533875A (ja) | 2010-06-30 | 2011-06-30 | 免疫グロブリン断片を用いた第7因子(FactorVIIa)薬物結合体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100062860A KR20120002129A (ko) | 2010-06-30 | 2010-06-30 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120002129A true KR20120002129A (ko) | 2012-01-05 |
Family
ID=45402578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100062860A Ceased KR20120002129A (ko) | 2010-06-30 | 2010-06-30 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130095090A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2588142A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013533875A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120002129A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103025358A (cg-RX-API-DMAC7.html) |
| AR (1) | AR082032A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI443106B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012002745A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101892687B1 (ko) | 2017-05-18 | 2018-08-28 | 세종대학교산학협력단 | 하이드라진 연료전지용 전극과 이를 포함하는 막 전극 접합체 및 연료전지 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0406605B8 (pt) * | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| CN104774269B (zh) * | 2013-08-16 | 2016-02-24 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
| JP2017513831A (ja) * | 2014-04-11 | 2017-06-01 | シーエスエル、リミテッド | 出血の予防および処置のための半減期延長型(half−life extended)第fviia因子タンパク質、ならびに、その投与レジメン |
| WO2017127679A1 (en) * | 2016-01-21 | 2017-07-27 | Protein Dynamic Solutions Llc | Method and system for spectral data analysis |
| CN111849945B (zh) * | 2019-04-25 | 2024-11-29 | 正大天晴药业集团股份有限公司 | 人凝血因子VIIa的纯化方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1656158B1 (en) * | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| EP1673453A2 (en) * | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybrid molecules having factor vii/viia activity |
| BRPI0406605B8 (pt) * | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| MX2008002395A (es) * | 2005-08-19 | 2008-03-18 | Neose Technologies Inc | Factor vii y factor viia glicopegilados. |
| WO2007140282A1 (en) * | 2006-05-24 | 2007-12-06 | Peg Biosciences | Peg linker compounds and biologically active conjugates thereof |
| US20100056428A1 (en) * | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| EP2300501B1 (en) * | 2008-07-23 | 2014-08-20 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
-
2010
- 2010-06-30 KR KR1020100062860A patent/KR20120002129A/ko not_active Ceased
-
2011
- 2011-06-29 AR ARP110102301A patent/AR082032A1/es unknown
- 2011-06-30 TW TW100123053A patent/TWI443106B/zh not_active IP Right Cessation
- 2011-06-30 JP JP2013518254A patent/JP2013533875A/ja active Pending
- 2011-06-30 CN CN2011800325807A patent/CN103025358A/zh active Pending
- 2011-06-30 WO PCT/KR2011/004796 patent/WO2012002745A2/en not_active Ceased
- 2011-06-30 EP EP11801151.9A patent/EP2588142A2/en not_active Withdrawn
- 2011-06-30 US US13/807,572 patent/US20130095090A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101892687B1 (ko) | 2017-05-18 | 2018-08-28 | 세종대학교산학협력단 | 하이드라진 연료전지용 전극과 이를 포함하는 막 전극 접합체 및 연료전지 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012002745A2 (en) | 2012-01-05 |
| EP2588142A2 (en) | 2013-05-08 |
| CN103025358A (zh) | 2013-04-03 |
| AR082032A1 (es) | 2012-11-07 |
| TW201217396A (en) | 2012-05-01 |
| JP2013533875A (ja) | 2013-08-29 |
| WO2012002745A3 (en) | 2012-04-26 |
| US20130095090A1 (en) | 2013-04-18 |
| TWI443106B (zh) | 2014-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9364520B2 (en) | Factor VIII conjugates | |
| TWI388570B (zh) | 包含具有三個官能端的非肽醯聚合物的多肽複合物 | |
| TWI423813B (zh) | 使用免疫球蛋白片段之長效β干擾素製劑 | |
| RU2620072C2 (ru) | ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ | |
| KR20080098216A (ko) | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 | |
| KR20110017420A (ko) | 폰 빌레브란트 질환의 치료를 위한 fviii 뮤테인 | |
| JP6676551B2 (ja) | 改変フォンウィルブランド因子 | |
| CN105229025B (zh) | 位点特异性胰岛素缀合物 | |
| JP2017165753A (ja) | 免疫グロブリン断片を用いたヒト卵胞刺激ホルモン持続性製剤 | |
| CN103930447A (zh) | 用于制备生理活性多肽复合物的方法 | |
| TW201546093A (zh) | 保留免疫球蛋白質Fc片段對FcRn之結合親和力之免疫球蛋白質Fc接合物 | |
| JP2026077647A (ja) | Glp-2の持続型結合体の液状製剤 | |
| TWI443106B (zh) | 使用免疫球蛋白片段之VIIa因子錯合物 | |
| KR20190013615A (ko) | 이두로네이트 2-설파타제 결합체 | |
| HK1196565B (en) | Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof | |
| HK1196565A (en) | Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof | |
| HK1196373A (en) | Method for preparing physiologically active polypeptide complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |